

Advanced Renal Cell Carcinoma - Pipeline Insight, 2021

<https://marketpublishers.com/r/AB4E27B01149EN.html>

Date: September 2021

Pages: 60

Price: US\$ 2,500.00 (Single User License)

ID: AB4E27B01149EN

Abstracts

This report can be delivered to the clients within 3-5 business days

DelveInsight's, "Advanced Renal Cell Carcinoma - Pipeline Insight, 2021," report provides comprehensive insights about 40+ companies and 40+ pipeline drugs in Advanced Renal Cell Carcinoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Advanced Renal Cell Carcinoma: Overview

Renal cell carcinoma is the most common type of kidney cancer. It usually starts as a tumor in one of your kidneys. And like other cancers, it can spread to other parts of your body. That's when doctors call it metastatic. As the tumor grows, it spreads into fat or major blood vessels around the kidney. It may also creep into the adrenal gland, which sits right on top of the organ. Kidney cancer most often spreads to the lungs and bones, but it can also go to the brain, liver, ovaries, and testicles. The process used to find out if cancer has spread within the kidney or to other parts of the body is called staging. The information gathered from the staging process determines the stage of the disease. It is important to know the stage in order to plan treatment. The following tests and procedures may be used in the staging process: CT scan; MRI (magnetic resonance

imaging); Chest x-ray; and bone scan. Different types of treatments are available for patients with renal cell cancer. Some treatments are standard (the currently used treatment), and some are being tested in clinical trials.

'Advanced Renal Cell Carcinoma - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Advanced Renal Cell Carcinoma pipeline landscape is provided which includes the disease overview and Advanced Renal Cell Carcinoma treatment guidelines. The assessment part of the report embraces, in depth Advanced Renal Cell Carcinoma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Advanced Renal Cell Carcinoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Advanced Renal Cell Carcinoma R&D. The therapies under development are focused on novel approaches to treat/improve Advanced Renal Cell Carcinoma.

Advanced Renal Cell Carcinoma Understanding

Advanced Renal Cell Carcinoma Emerging Drugs Chapters

This segment of the Advanced Renal Cell Carcinoma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Advanced Renal Cell Carcinoma Emerging Drugs

Atezolizumab: Roche

Atezolizumab is a humanized monoclonal antibody immune checkpoint inhibitor that selectively binds to PD-L1 to stop the interaction between PD-1 and B7. 1 (ie, CD80 receptors). The antibody still allows interaction between PD-L2 and PD-1. Currently, it is in Phase III stage of clinical trial evaluation to treat advanced Renal Cell Carcinoma.

Bempegaldesleukin (NKTR-214): Nektar Therapeutics

Bempegaldesleukin is a CD122-preferential IL-2 pathway agonist designed to stimulate the patient's own immune system to fight cancer. Bempegaldesleukin is designed to grow specific cancer-killing T cells and natural killer (NK) cell populations in the body which fight cancer, which are known as endogenous tumor-infiltrating lymphocytes (TILs). Bempegaldesleukin stimulates these cancer-killing immune cells in the body by targeting CD122 specific receptors found on the surface of these immune cells, known as CD8+ effector T cells and NK cells. CD122, which is also known as the Interleukin-2 receptor beta subunit, is a key signaling receptor that is known to increase proliferation of these effector T cells. In clinical and preclinical studies, treatment with bempegaldesleukin resulted in expansion of these cells and mobilization into the tumor micro-environment. Bempegaldesleukin has an antibody-like dosing regimen similar to the existing checkpoint inhibitor class of approved medicines.

Further product details are provided in the report.

Advanced Renal Cell Carcinoma: Therapeutic Assessment

This segment of the report provides insights about the different Advanced Renal Cell Carcinoma drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Advanced Renal Cell Carcinoma

There are approx. 40+ key companies which are developing the therapies for Advanced Renal Cell Carcinoma. The companies which have their Advanced Renal Cell Carcinoma drug candidates in the most advanced stage, i.e. phase III include, Roche.

Phases

DelveInsight's report covers around 40+ products under different phases of clinical development like

Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Advanced Renal Cell Carcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral

Parenteral

intravenous

Subcutaneous

Topical.

Molecule Type

Products have been categorized under various Molecule types such as

Monoclonal Antibody

Peptides

Polymer

Small molecule

Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Advanced Renal Cell Carcinoma: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Advanced Renal Cell Carcinoma therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Advanced Renal Cell Carcinoma drugs.

Advanced Renal Cell Carcinoma Report Insights

Advanced Renal Cell Carcinoma Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

Advanced Renal Cell Carcinoma Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Advanced Renal Cell Carcinoma drugs?

How many Advanced Renal Cell Carcinoma drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Advanced Renal Cell Carcinoma?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Advanced Renal Cell Carcinoma therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Advanced Renal Cell Carcinoma and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

Roche

Nektar Therapeutic

MedImmune LLC

ColImmune

X4 Pharmaceuticals

Daiichi Sankyo, Inc.

Eli Lilly and Company

Jiangsu HengRui Medicine Co., Ltd.

Allogene Therapeutics

Apexigen, Inc.

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Aravive, Inc.

Arrowhead Pharmaceuticals

Merck

Apollomics

Astex Pharmaceuticals

Peloton Therapeutics, Inc.

Infinity Pharmaceuticals

Surface Oncology

AO GENERIUM

CRISPR Therapeutics AG

Key Products

Atezolizumab

Bempegaldesleukin

MEDI5752

CMN-001

X4P-001

PT2385

GNR-051

CTX130

Guadecitabine

SRF388

ARO-HIF2

DS-6000a

Abemaciclib

SHR-1210

ALLO-316

APX005M

TQB2450

AVB-S6-500

APL-501

IPI-549

Contents

Introduction

Executive Summary

Advanced Renal Cell Carcinoma: Overview

Causes

Mechanism of Action

Signs and Symptoms

Diagnosis

Disease Management

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

Advanced Renal Cell Carcinoma – DelveInsight's Analytical Perspective

Late Stage Products (Phase III)

Comparative Analysis

Atezolizumab: Roche

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.

Mid Stage Products (Phase II)

Comparative Analysis

Guadecitabine: Astex Pharmaceuticals

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.

Early Stage Products (Phase I)

Comparative Analysis

MEDI5752: MedImmune

Product Description

Research and Development
Product Development Activities
Drug profiles in the detailed report.
Inactive Products
Comparative Analysis
Advanced Renal Cell Carcinoma Key Companies
Advanced Renal Cell Carcinoma Key Products
Advanced Renal Cell Carcinoma- Unmet Needs
Advanced Renal Cell Carcinoma- Market Drivers and Barriers
Advanced Renal Cell Carcinoma- Future Perspectives and Conclusion
Advanced Renal Cell Carcinoma Analyst Views
Advanced Renal Cell Carcinoma Key Companies
Appendix

List Of Tables

LIST OF TABLES

Table 1 Total Products for Advanced Renal Cell Carcinoma

Table 2 Late Stage Products

Table 3 Mid Stage Products

Table 4 Early Stage Products

Table 5 Pre-clinical & Discovery Stage Products

Table 6 Assessment by Product Type

Table 7 Assessment by Stage and Product Type

Table 8 Assessment by Route of Administration

Table 9 Assessment by Stage and Route of Administration

Table 10 Assessment by Molecule Type

Table 11 Assessment by Stage and Molecule Type

Table 12 Inactive Products

List Of Figures

LIST OF FIGURES

Figure 1 Total Products for Advanced Renal Cell Carcinoma

Figure 2 Late Stage Products

Figure 3 Mid Stage Products

Figure 4 Early Stage Products

Figure 5 Preclinical and Discovery Stage Products

Figure 6 Assessment by Product Type

Figure 7 Assessment by Stage and Product Type

Figure 8 Assessment by Route of Administration

Figure 9 Assessment by Stage and Route of Administration

Figure 10 Assessment by Molecule Type

Figure 11 Assessment by Stage and Molecule Type

Figure 12 Inactive Products

I would like to order

Product name: Advanced Renal Cell Carcinoma - Pipeline Insight, 2021

Product link: <https://marketpublishers.com/r/AB4E27B01149EN.html>

Price: US\$ 2,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/AB4E27B01149EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970